MET and esophageal cancer: Notably, previous studies reported that miR-454-3p inhibited AKT signaling pathway by targeting insulinlike growth factor 2 mRNA-binding protein 1 (IGF2BP1) in esophageal cancer (ESCA) (35) and targeting c-met in nasopharyngeal carcinoma (36), resulting in the suppression of cell growth and enhancement of cisplatin sensitivity.